A shortage of participants means that paediatric trials take longer and there is less financial incentive for pharmaceutical companies. Although the number of trials in kids has increased over the years, lack of data is still delaying paediatric labelling of drugs and leaving physicians with little information about whether the drugs are effective or safe in children. The whole article was published by Nature.
IMAGE: Global Panorama — Flickr